CoLucid Pharmaceuticals, Inc. Release: New Study Shows That Majority of Acute Migraine Patients Have Cardiovascular Disease Risk Factors and One Third Have Cardiovascular Disease
12/21/2012 8:22:50 AM
More...
|
CoLucid Pharmaceuticals, Inc. to Attend the BIO-Europe 2012 Meeting in Hamburg, Germany
11/8/2012 10:03:01 AM
More...
|
CoLucid Pharmaceuticals, Inc. Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
9/18/2012 10:29:01 AM
More...
|
CoLucid Pharmaceuticals, Inc. Founder Passes Away
2/8/2012 6:49:13 AM
More...
|
CoLucid Pharmaceuticals, Inc. to Present at the Biotech Showcase During J.P. Morgan Healthcare Conference
1/4/2012 1:31:25 PM
More...
|
CoLucid Pharmaceuticals, Inc. to Present at Sofinnova Japan Biopharma Partnering Conference on Tuesday, October 4th in Tokyo, Japan
9/29/2011 11:51:10 AM
More...
|
CoLucid Pharmaceuticals, Inc. Announces Study Data Documenting Oral Efficacy of Lasmiditan (COL-144), a Selective 5-HT1F Receptor Agonist, in the Treatment of Acute Migraine Attacks
6/9/2010 11:06:50 AM
More...
|
CoLucid Pharmaceuticals, Inc. to Present at the Oppenheimer 20th Annual Healthcare Conference on November 3, 2009
10/27/2009 9:49:17 AM
More...
|
CoLucid Pharmaceuticals, Inc. Names Linda Hogan VP of Business Development
10/28/2008 7:54:36 AM
More...
|
CoLucid Pharmaceuticals, Inc. Release: Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
9/9/2008 2:07:08 PM
More...
|
|